Innovent Biologics, Inc. (HKG:1801)
86.80
-1.50 (-1.70%)
Nov 11, 2026, 4:08 PM HKT
Innovent Biologics Employees
Innovent Biologics had 8,754 employees as of June 30, 2026. The number of employees increased by 1,252 or 16.69% since the number was reported on December 31, 2025. That makes Innovent Biologics the 3,723rd largest employer in the world and 312th in Hong Kong.
Employees
8,754
Change
1,252
Growth
16.69%
Revenue / Employee
2.07M HKD
Profits / Employee
162.53K HKD
Market Cap
151.11B
Employees Chart
| Date | Employees | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 8,754 | 1,252 | 16.69% |
| Dec 31, 2025 | 7,502 | 1,843 | 32.57% |
| Dec 31, 2024 | 5,659 | 787 | 16.15% |
| Dec 31, 2023 | 4,872 | -422 | -7.97% |
| Dec 31, 2022 | 5,294 | -274 | -4.92% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Sino Biopharmaceutical | 22,838 |
| WuXi Biologics | 14,705 |
| BeOne Medicines AG | 12,000 |
| Genscript Biotech | 6,135 |
| 3SBio | 6,068 |
| Akeso | 4,082 |
| Shanghai Henlius Biotech | 4,082 |
| RemeGen | 3,145 |
Innovent Biologics News
- 2 days ago - Innovent's Sintbilo Cuts LDL Cholesterol Over 60% In Phase 3 Trial - Nasdaq
- 2 days ago - Innovent Biologics announces Sintbilo achieved primary endpoint - TheFly
- 2 days ago - Innovent Announces Phase 3 CREDIT-5 Study Met Primary Endpoint, SINTBILO® (Tafolecimab Injection) as First-line Monotherapy Treatment for Hyperlipidemia Demonstrated Potent Lipid-lowering Efficacy - PRNewsWire
- 16 days ago - Innovent Announces NMPA Acceptance of a New Indication Application of Sintilimab for the Treatment of Advanced Melanoma - PRNewsWire
- 16 days ago - 2026 ESMO | Innovent Presents Multiple Clinical Data Updates for IBI363/TAK-928, a PD-1/Alpha-Biased IL-2 Bispecific Fusion Protein - PRNewsWire
- 16 days ago - Innovent Biologics presents Phase 2 data for IBI354 at ESMO Congress - TheFly
- 17 days ago - 2026 ESMO | Innovent Presented Phase 1 Study Data for IBI3001, a First-in-Class EGFR/B7H3 Bispecific ADC - PRNewsWire
- 17 days ago - 2026 ESMO | Innovent Announcement Phase 2 Data Presentation for IBI354 (HER2 ADC) In First-line Treatment of Breast Cancer - PRNewsWire